Silo Pharma (NASDAQ:SILO) versus Pulmatrix (NASDAQ:PULM) Head-To-Head Contrast

Silo Pharma (NASDAQ:SILO) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Earnings & Valuation

This table compares Silo Pharma and Pulmatrix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70,000.00	33.84	-$4.23 million	($4.36)	-0.34
Pulmatrix	$7.81 million	0.66	-$5.16 million	($1.10)	-1.28

Silo Pharma has higher earnings, but lower revenue than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Silo Pharma has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.

Profitability

This table compares Silo Pharma and Pulmatrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Pulmatrix	N/A	-125.65%	-95.19%

Analyst Ratings

This is a summary of current ratings and target prices for Silo Pharma and Pulmatrix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1	0	0	0	1.00
Pulmatrix	1	0	0	0	1.00

Institutional & Insider Ownership

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Silo Pharma beats Pulmatrix on 6 of the 11 factors compared between the two stocks.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.